Founded in 2016, Maxwell Biosciences is a preclinical stage biotech company focused on the treatment of Infectious Disease. Maxwell’s First-in-Class CLAROMER™ brand drug discovery platform has proven pre-clinical efficacy against bacterial, fungal, mold, yeast, biofilm and viral infections while safely avoiding healthy cells. Maxwell’s biomimetic platform produces synthetic, highly biostable, highly scalable low-molecular weight compounds that imitate key components of the immune system, humanity’s greatest asset in fighting disease. Maxwell’s technology is protected by granted patents and is led by a world-class team of experienced life science executives.
Visit https://maxwellbiosciences.com to learn more.